Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback